Dong-A ST Co., Ltd. (170900.KS)
KRW 45000.0
(0.33%)
KRW 45000.0
(0.33%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 161.99 Billion KRW | -34.46% |
| 2022 | 247.14 Billion KRW | 58.31% |
| 2021 | 156.11 Billion KRW | 1.44% |
| 2020 | 153.89 Billion KRW | 35.21% |
| 2019 | 113.82 Billion KRW | 62.71% |
| 2018 | 69.95 Billion KRW | 16.8% |
| 2017 | 59.89 Billion KRW | 50.13% |
| 2016 | 39.89 Billion KRW | -82.51% |
| 2015 | 228.11 Billion KRW | -28.94% |
| 2014 | 321.01 Billion KRW | 17.01% |
| 2013 | 274.35 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 328.26 Billion KRW | 42.42% |
| 2024 Q1 | 230.48 Billion KRW | 42.28% |
| 2023 Q4 | 161.99 Billion KRW | -24.73% |
| 2023 Q1 | 246.23 Billion KRW | -0.37% |
| 2023 FY | 161.99 Billion KRW | -34.46% |
| 2023 Q3 | 215.22 Billion KRW | -33.8% |
| 2023 Q2 | 325.11 Billion KRW | 32.03% |
| 2022 FY | 247.14 Billion KRW | 58.31% |
| 2022 Q1 | 216.43 Billion KRW | 38.64% |
| 2022 Q2 | 228.73 Billion KRW | 5.68% |
| 2022 Q4 | 247.14 Billion KRW | -1.56% |
| 2022 Q3 | 251.05 Billion KRW | 9.76% |
| 2021 Q4 | 156.11 Billion KRW | -11.4% |
| 2021 Q2 | 102.97 Billion KRW | -32.92% |
| 2021 FY | 156.11 Billion KRW | 1.44% |
| 2021 Q1 | 153.49 Billion KRW | -0.26% |
| 2021 Q3 | 176.19 Billion KRW | 71.11% |
| 2020 Q1 | 114.34 Billion KRW | 0.46% |
| 2020 FY | 153.89 Billion KRW | 35.21% |
| 2020 Q4 | 153.89 Billion KRW | -0.45% |
| 2020 Q3 | 154.59 Billion KRW | 0.56% |
| 2020 Q2 | 153.72 Billion KRW | 34.45% |
| 2019 Q3 | 143.52 Billion KRW | 0.47% |
| 2019 Q4 | 113.82 Billion KRW | -20.69% |
| 2019 Q1 | 71.53 Billion KRW | 2.26% |
| 2019 FY | 113.82 Billion KRW | 62.71% |
| 2019 Q2 | 142.84 Billion KRW | 99.7% |
| 2018 FY | 69.95 Billion KRW | 16.8% |
| 2018 Q4 | 69.95 Billion KRW | -36.35% |
| 2018 Q3 | 109.9 Billion KRW | 0.01% |
| 2018 Q2 | 109.89 Billion KRW | 0.01% |
| 2018 Q1 | 109.87 Billion KRW | 83.46% |
| 2017 Q1 | 39.9 Billion KRW | 0.02% |
| 2017 Q2 | 39.91 Billion KRW | 0.03% |
| 2017 Q3 | 39.92 Billion KRW | 0.03% |
| 2017 Q4 | 59.89 Billion KRW | 50.02% |
| 2017 FY | 59.89 Billion KRW | 50.13% |
| 2016 Q2 | 148.63 Billion KRW | -25.55% |
| 2016 FY | 39.89 Billion KRW | -82.51% |
| 2016 Q4 | 39.89 Billion KRW | -42.87% |
| 2016 Q3 | 69.82 Billion KRW | -53.02% |
| 2016 Q1 | 199.64 Billion KRW | -12.48% |
| 2015 Q4 | 228.11 Billion KRW | -13.16% |
| 2015 FY | 228.11 Billion KRW | -28.94% |
| 2015 Q3 | 262.67 Billion KRW | -6.02% |
| 2015 Q2 | 279.49 Billion KRW | -13.25% |
| 2015 Q1 | 322.17 Billion KRW | 0.36% |
| 2014 FY | 321.01 Billion KRW | 17.01% |
| 2014 Q1 | 275.92 Billion KRW | 0.57% |
| 2014 Q2 | 315.45 Billion KRW | 14.32% |
| 2014 Q3 | 248.94 Billion KRW | -21.08% |
| 2014 Q4 | 321.01 Billion KRW | 28.95% |
| 2013 Q2 | 221.89 Billion KRW | 0.0% |
| 2013 Q3 | 242.57 Billion KRW | 9.32% |
| 2013 Q4 | 274.35 Billion KRW | 13.1% |
| 2013 FY | 274.35 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -904.434% |
| Yuhan Corporation | 60.23 Billion KRW | -168.939% |
| Yuhan Corporation | 60.23 Billion KRW | -168.939% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -1087.62% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -1087.62% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -1087.62% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -442.203% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | -226.804% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 19.83% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -439.973% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -439.973% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -439.973% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -158999.816% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | -124.638% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -774.573% |
| HANDOK Inc. | 123.78 Billion KRW | -30.871% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -1442.78% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -33950.314% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | -106.293% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -406.225% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -135256.018% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | -368.527% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | -301.19% |
| Boryung Corporation | 151.7 Billion KRW | -6.779% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -27798.562% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -3787.831% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -2577.552% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -2577.552% |
| Suheung Co., Ltd. | 74 Billion KRW | -118.887% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -751.35% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -27341.876% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -52656.435% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -1187.264% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -73882.087% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -73882.087% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -1377.691% |
| CKD Bio Corp. | 69.43 Billion KRW | -133.313% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | -73.41% |
| JW Holdings Corporation | 20.65 Billion KRW | -684.186% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | -33.878% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | -97.483% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -439.973% |
| JW Lifescience Corporation | 168 Million KRW | -96323.76% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -992.681% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -3538.629% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -10031.803% |